SEC Form 4 · accession 0000899243-18-006846
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert S Fishman
Officer — Chief Medical Officer
Period of report
Mar 7, 2018
Accepted (ET)
Mar 8, 2018 · 7:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 7, 2018 | M | 8,000 | $3.51 | A | 8,000 | D | |
| Common StockF2 | Mar 7, 2018 | S | 8,000 | $15.6654 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $3.51 | Mar 7, 2018 | M | 8,000 | D | — | Sep 29, 2025 | Common Stock | 8,000 | 393,000 | D |
Explanation of responses
- F1These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares.
- F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $15.34 to $15.88 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
- F3Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019.